Drug combination study for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has returned or spread and failed first-line treatment with cisplatin-based therapy
- You are between 18 and 70 years old
- You are physically active enough to care for yourself (ECOG 0-1)
- You have a tumor that can be measured on scans (not just in bone)
- You are willing to provide a tumor sample for testing
- Your blood counts and liver/kidney function are within a safe range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests two drugs—scipibaimab and tislelizumab—given together for people with nasopharyngeal cancer that has not responded to first-line platinum chemotherapy and a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with standard chemotherapy and radiation for people with newly diagnosed, stage IVA nasopharyngeal cancer that has spread to lymph nodes but not to distant organs. The goal is to see if this approach can improve outcomes.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy before standard radiation for advanced nasopharyngeal cancer. It aims to shrink tumors and improve outcomes.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.